CLRB (Cellectar Biosciences) Moat Score: 4/10 (As of Jun. 27, 2026)


CLRB Cellectar Biosciences Inc CLRB
28 GF Score
Price $2.50
! 1 Warning Sign
View Full Analysis

What is Cellectar Biosciences Moat Score?

Cellectar Biosciences CLRB +1.20% 28 Moat Score is 4 as of Jun. 27, 2026. GuruFocus rates CLRB with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,404 Biotechnology companies, Cellectar Biosciences ranks better than 88.82% on this metric.

Cellectar Biosciences has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Cellectar Biosciences has Narrow Moat: Cellectar Biosciences Inc has discernible but modest advantages through its intellectual property and R&D capabilities. However, it lacks broader market leadership and customer loyalty.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cellectar Biosciences might have Narrow Moat - Discernible but modest moat.

Cellectar Biosciences  (NAS:CLRB) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cellectar Biosciences Moat Score Related Terms

CLRB vs PTN, PLUR, VTGN: Moat Score Comparison

For the Biotechnology subindustry, Cellectar Biosciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cellectar Biosciences Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Cellectar Biosciences's Moat Score falls into.


CLRB
28GF Score
Cellectar Biosciences Inc CLRB
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Cellectar Biosciences (CLRB) has a Moat Score of 4 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Cellectar Biosciences ranks #157 out of 1404 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Cellectar Biosciences' Moat Score too high?
Cellectar Biosciences' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Cellectar Biosciences' value of 4 is 100% above this industry median. Based on the distribution chart, Cellectar Biosciences ranks #157 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cellectar Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Cellectar Biosciences' Moat Score compare to PTN and PLUR?
According to the Biotechnology industry distribution chart, Cellectar Biosciences ranks #157 out of 1404 companies for Moat Score. This places Cellectar Biosciences in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Cellectar Biosciences' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cellectar Biosciences's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellectar Biosciences's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectar Biosciences stock overvalued right now?
Cellectar Biosciences (CLRB) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Cellectar Biosciences' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Cellectar Biosciences (CLRB), the current Moat Score is 4 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cellectar Biosciences Business Description

Address 100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
28GF Score

Get the complete analysis for CLRB

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.50
Price